# Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

> **NCT05641298** · PHASE2 · WITHDRAWN · sponsor: **Aceragen**

## Conditions studied

- Cystic Fibrosis
- Cystic Fibrosis Pulmonary Exacerbation

## Interventions

- **DRUG:** Sodium Fusidate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05641298
- **Lead sponsor:** Aceragen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-10
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Corporate finances
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641298, "Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05641298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*